Full Press Release Details
| November 2, 2017 | |
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a press release on "Dr.
Reddy's Laboratories announces the launch of generic Azacitidine for Injection in the Canadian Market".
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary | |
| Encl: As above | |
| CC:- New York Stock Exchange Inc.(Stock Code :RDY) |
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | INVESTOR RELATIONS | MEDIA RELATIONS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-49002135) | CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40- 49002121) |
Reddy's Laboratories announces the launch of
Azacitidine for Injection in the Canadian Market
Hyderabad, India and Princeton, NJ, USA. November 02, 2017-
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY) is pleased to announce that generic Azacitidine for injection 100
mg/vial, a bioequivalent generic version of VIDAZA (azacitidine for injection), is approved by Health Canada.
"Bringing Azacitidine for Injection to the Canadian market
at this time is very important for us, as well as for our customers and their patients," says Alok Sonig, Executive Vice
President and Head of the North America Generics business at Dr. Reddy's. "This launch represents Dr. Reddy's
commitment to make affordable injectable drugs available in Canada." Dr. Reddy's is first to market with this Azacitidine
for injection in Canada.
Vinod Ramachandran, Ph.D., Country Manager, Dr. Reddy's Canada
says that "The approval and launch of Azacitidine for injection is an important milestone for Dr. Reddy's in Canada. The
launch of first generic Azacitidine for injection is another step in our long-term commitment to bring more cost-effective options
to Canadian patients."
VIDAZA is a trademark of Celgene.
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd.
(BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics
and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical
services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,
diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets
include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency
exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration
The company assumes no obligation to update any information contained